Multivalent design of the monoclonal SynO2 antibody improves binding strength to soluble α-Synuclein aggregates

References

• Luo SX, Huang EJ. Dopaminergic neurons and brain reward pathways. Am J Pathol. 2016;186:478–12. doi:10.1016/j.ajpath.2015.09.023.
   PubMed Web of Science ®Google Scholar
• Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–52. doi:10.1136/jnnp.51.6.745.
   PubMed Web of Science ®Google Scholar
• Bartels T, Choi JG, Selkoe DJ. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477:107–10. doi:10.1038/nature10324.
   PubMed Web of Science ®Google Scholar
• Burré J, Sharma M, Südhof TC. α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci. 2014;111(40):E4274–E83. doi:10.1073/pnas.1416598111.
   PubMed Web of Science ®Google Scholar
• Killinger BA, Melki R, Brundin P, Kordower JH. Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let’s talk about the lipids in the room. Npj Park Dis. 2019;5(1):23. doi:10.1038/s41531-019-0095-3.
   PubMedGoogle Scholar
• Luth ES, Bartels T, Dettmer U, Kim NC, Selkoe DJ. Purification of α-Synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. Biochemistry. 2015;54(2):279–92. doi:10.1021/bi501188a.
   PubMed Web of Science ®Google Scholar
• Cremades N, Cohen SIA, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, et al. Direct observation of the interconversion of normal and toxic forms of α-Synuclein. Cell. 2012;149(5):1048–59. doi:10.1016/j.cell.2012.03.037.
   PubMed Web of Science ®Google Scholar
• de Oliveira GAP, Silva JL. Alpha-Synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson’s disease. Commun Biol. 2019;2(1):374. doi:10.1038/s42003-019-0598-9.
   PubMedGoogle Scholar
• Mirecka EA, Shaykhalishahi H, Gauhar A, Akgül Ş, Lecher J, Willbold D, Stoldt M, Hoyer W. Sequestration of a β-hairpin for control of α-Synuclein aggregation. Angew Chem Int Ed. 2014;53(16):4227–30. doi:10.1002/anie.201309001.
   PubMed Web of Science ®Google Scholar
• Salveson PJ, Spencer RK, Nowick JS. X-Ray crystallographic structure of oligomers formed by a toxic β-hairpin derived from α-Synuclein: trimers and Higher-Order oligomers. J Am Chem Soc. 2016;138:4458–67. doi:10.1021/jacs.5b13261.
   PubMed Web of Science ®Google Scholar
• Yu H, Han W, Ma W, Schulten K. Transient β-hairpin formation in α-Synuclein monomer revealed by coarse-grained molecular dynamics simulation. J Chem Phys. 2015;143:243142. doi:10.1063/1.4936910.
   PubMed Web of Science ®Google Scholar
• Celej MS, Sarroukh R, Goormaghtigh E, Fidelio GD, Ruysschaert J-M, Raussens V. Toxic prefibrillar α-Synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure. Biochem J. 2012;443:719–26. doi:10.1042/BJ20111924.
   PubMed Web of Science ®Google Scholar
• Kim H-Y, Cho M-K, Kumar A, Maier E, Siebenhaar C, Becker S, Fernandez CO, Lashuel HA, Benz R, Lange A, et al. Structural properties of pore-forming oligomers of α-Synuclein. J Am Chem Soc. 2009;131(47):17482–89. doi:10.1021/ja9077599.
   PubMed Web of Science ®Google Scholar
• Cascella R, Chen SW, Bigi A, Camino JD, Xu CK, Dobson CM, Chiti F, Cremades N, Cecchi C. The release of toxic oligomers from α-Synuclein fibrils induces dysfunction in neuronal cells. Nat Commun. 2021;12(1):1814. doi:10.1038/s41467-021-21937-3.
   PubMed Web of Science ®Google Scholar
• Fusco G, Chen SW, Williamson PTF, Cascella R, Perni M, Jarvis JA, Cecchi C, Vendruscolo M, Chiti F, Cremades N, et al. Structural basis of membrane disruption and cellular toxicity by α-Synuclein Oligomers. Sci. 2017;358(6369):1440–43. doi:10.1126/science.aan6160.
   PubMed Web of Science ®Google Scholar
• Choi B-K, Choi M-G, Kim J-Y, Yang Y, Lai Y, Kweon D-H, Lee NK, Shin Y-K. Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci. 2013;110(10):4087–92. doi:10.1073/pnas.1218424110.
   PubMed Web of Science ®Google Scholar
• Deas E, Cremades N, Angelova PR, Ludtmann MHR, Yao Z, Chen S, Horrocks MH, Banushi B, Little D, Devine MJ, et al. Alpha-Synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson’s disease. Antioxid Redox Signal. 2016;24(7):376–91. doi:10.1089/ars.2015.6343.
   PubMed Web of Science ®Google Scholar
• Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, Hu X, McCoy J, Chu CT, Burton EA, et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci Transl Med. 2016;8. doi:10.1126/scitranslmed.aaf3634.
   PubMed Web of Science ®Google Scholar
• Ludtmann MHR, Angelova PR, Horrocks MH, Choi ML, Rodrigues M, Baev AY, Berezhnov AV, Yao Z, Little D, Banushi B, et al. α-Synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson’s disease. Nat Commun. 2018;9:2293. doi:10.1038/s41467-018-04422-2.
   PubMed Web of Science ®Google Scholar
• Daniele SG, Béraud D, Davenport C, Cheng K, Yin H, Maguire-Zeiss KA. Activation of MyD88-dependent TLR1/2 signaling by misfolded α-Synuclein, a protein linked to neurodegenerative disorders. Sci Signal. 2015;8. doi:10.1126/scisignal.2005965.
   PubMed Web of Science ®Google Scholar
• Lee H-J, Suk J-E, Patrick C, Bae E-J, Cho J-H, Rho S, Hwang D, Masliah E, Lee S-J. Direct Transfer of α-Synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem. 2010;285:9262–72. doi:10.1074/jbc.M109.081125.
   PubMed Web of Science ®Google Scholar
• Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K. Cell-produced α-Synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010;30(20):6838–51. doi:10.1523/JNEUROSCI.5699-09.2010.
   PubMed Web of Science ®Google Scholar
• Lee H-J, Kim C, Lee S-J. Alpha-Synuclein stimulation of astrocytes: potential role for neuroinflammation and neuroprotection. Oxid Med Cell Longev. 2010;3:283–87. doi:10.4161/oxim.3.4.12809.
   PubMed Web of Science ®Google Scholar
• Lee H-J, Suk J-E, Bae E-J, Lee S-J. Clearance and deposition of extracellular α-Synuclein aggregates in microglia. Biochem Biophys Res Commun. 2008;372(3):423–28. doi:10.1016/j.bbrc.2008.05.045.
   PubMed Web of Science ®Google Scholar
• Brahic M, Bousset L, Bieri G, Melki R, Gitler AD. Axonal transport and secretion of fibrillar forms of α-Synuclein, Aβ42 peptide and HTTExon 1. Acta Neuropathol (Berl). 2016;131(4):539–48. doi:10.1007/s00401-016-1538-0.
   PubMed Web of Science ®Google Scholar
• Rey NL, Petit GH, Bousset L, Melki R, Brundin P. Transfer of human α-Synuclein from the olfactory bulb to Interconnected brain regions in mice. Acta Neuropathol (Berl). 2013;126(4):555–73. doi:10.1007/s00401-013-1160-3.
   PubMed Web of Science ®Google Scholar
• Fjord-Larsen L, Thougaard A, Wegener KM, Christiansen J, Larsen F, Schrøder-Hansen LM, Kaarde M, Ditlevsen DK. Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-Synuclein in development for treatment of synucleinopathies. MAbs. 2021;13(1):1994690. doi:10.1080/19420862.2021.1994690.
   PubMed Web of Science ®Google Scholar
• Kalluri H, Zadikoff C, Rueter L, Graff O, Xiong H. Randomized, placebo-controlled single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of ABBV-0805, an anti-alpha-Synuclein monoclonal antibody in healthy subjects [abstract]. Mov Disord. 2021;36. doi:10.1002/mds.28794.
   Web of Science ®Google Scholar
• Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, et al. Trial of cinpanemab in early Parkinson’s disease. N Engl J Med. 2022;387(5):408–20. doi:10.1056/NEJMoa2203395.
   PubMed Web of Science ®Google Scholar
• Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay J-P, et al. Trial of prasinezumab in early-stage Parkinson’s disease. N Engl J Med. 2022;387(5):421–32. doi:10.1056/NEJMoa2202867.
   PubMed Web of Science ®Google Scholar
• Schofield DJ, Irving L, Calo L, Bogstedt A, Rees G, Nuccitelli A, Narwal R, Petrone M, Roberts J, Brown L, et al. Preclinical development of a high affinity α-Synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-Synuclein and attenuate α-Synuclein spreading in vivo. Neurobiol Dis. 2019;132:104582. doi:10.1016/j.nbd.2019.104582.
   PubMed Web of Science ®Google Scholar
• Roshanbin S, Julku U, Xiong M, Eriksson J, Masliah E, Hultqvist G, Bergström J, Ingelsson M, Syvänen S, Sehlin D. Reduction of ΑSYN pathology in a mouse model of PD using a brain-penetrating bispecific antibody. Pharmaceutics. 2022;14(7):1412. doi:10.3390/pharmaceutics14071412.
   PubMed Web of Science ®Google Scholar
• Oliveira LMA, Gasser T, Edwards R, Zweckstetter M, Melki R, Stefanis L, Lashuel HA, Sulzer D, Vekrellis K, Halliday GM, et al. Alpha-Synuclein Research: defining strategic moves in the battle against Parkinson’s disease. Npj Park Dis. 2021;7(1):65. doi:10.1038/s41531-021-00203-9.
   PubMed Web of Science ®Google Scholar
• Rofo F, Meier SR, Metzendorf NG, Morrison JI, Petrovic A, Syvänen S, Sehlin D, Hultqvist G. A brain-targeting bispecific-multivalent antibody clears soluble amyloid-beta aggregates in Alzheimer’s disease mice. Neurotherapeutics. 2022;19(5):1588–602. doi:10.1007/s13311-022-01283-y.
   PubMed Web of Science ®Google Scholar
• Rofo F, Buijs J, Falk R, Honek K, Lannfelt L, Lilja AM, Metzendorf NG, Gustavsson T, Sehlin D, Söderberg L, et al. Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. Transl Neurodegener. 2021;10(1):38. doi:10.1186/s40035-021-00258-x.
   PubMed Web of Science ®Google Scholar
• van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. doi:10.1056/NEJMoa2212948.
   PubMed Web of Science ®Google Scholar
• Vaikath NN, Majbour NK, Paleologou KE, Ardah MT, van Dam E, van de Berg WDJ, Forrest SL, Parkkinen L, Gai W-P, Hattori N, et al. Generation and Characterization of novel conformation-specific monoclonal antibodies for α-Synuclein pathology. Neurobiol Dis. 2015;79:81–99. doi:10.1016/j.nbd.2015.04.009.
   PubMed Web of Science ®Google Scholar
• Castonguay A-M, Gravel C, Lévesque M. Treating Parkinson’s disease with antibodies: previous studies and future directions. J Park Dis. 2021;11(1):71–92. doi:10.3233/JPD-202221.
   Web of Science ®Google Scholar
• Morrison JI, Metzendorf NG, Rofo F, Petrovic A, Hultqvist G A single chain fragment constant (scFc) design enables easy production of a monovalent BBB transporter and provides an improved brain Uptake at elevated doses. J Neurochem. 2023; 15768, doi:10.1111/jnc.15768.
   Web of Science ®Google Scholar
• Bondza S, ten Broeke T, Nestor M, Leusen JHW, Buijs J. Bivalent binding on cells varies between anti-CD20 antibodies and is dose-dependent. MAbs. 2020;12(1):1792673. doi:10.1080/19420862.2020.1792673.
   PubMed Web of Science ®Google Scholar
• Kumar ST, Jagannath S, Francois C, Vanderstichele H, Stoops E, Lashuel HA. How specific are the conformation-specific α-Synuclein antibodies? Characterization and validation of 16 α-Synuclein conformation-specific antibodies using well-characterized preparations of α-Synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol Dis. 2020;146:105086. doi:10.1016/j.nbd.2020.105086.
   PubMed Web of Science ®Google Scholar
• Yusakul G, Sakamoto S, Pongkitwitoon B, Tanaka H, Morimoto S. Effect of Linker length between variable domains of single chain variable fragment antibody against Daidzin on its reactivity. Biosci Biotechnol Biochem. 2016;80:1306–12. doi:10.1080/09168451.2016.1156482.
   PubMed Web of Science ®Google Scholar
• Fang XT, Sehlin D, Lannfelt L, Syvänen S, Hultqvist G. Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells. Biol Proced Online. 2017;19(1):11. doi:10.1186/s12575-017-0060-7.
   PubMedGoogle Scholar
• Almandoz-Gil L, Welander H, Ihse E, Khoonsari PE, Musunuri S, Lendel C, Sigvardson J, Karlsson M, Ingelsson M, Kultima K, et al. Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-Synuclein through different pathways. Free Radic Biol Med. 2017;110:421–31. doi:10.1016/j.freeradbiomed.2017.07.004.
   PubMed Web of Science ®Google Scholar
• Hunter WM, Greenwood FC. Preparation of Iodine-131 labelled human growth hormone of high specific activity. Nature. 1962;194(4827):495–96. doi:10.1038/194495a0.
   PubMed Web of Science ®Google Scholar